Image provided by: University of Oregon Libraries; Eugene, OR
About Just out. (Portland, OR) 1983-2013 | View Entire Issue (Jan. 1, 1990)
Vaccine works in monkeys A vaccine made from killed SIV, the AIDS vims for monkeys, protected eight out of nine monkeys from later infection with SIV. Researchers at Tulane University injected monkeys with vaccine and repeated the injections one month, two months, and 13 months later. Next the researchers tried to infect the monkeys by injecting them with concentrated solutions of SIV. Usually monkeys infected with SIV develop AIDS and die within seven months. But all of the vaccinated monkeys were alive one year after they were injected with concentrated SIV, and eight of the nine monkeys remained uninfected. These scientists hope to develop a vaccine made from killed HIV that will work with humans. Reference: M. Murphy-Corb and others. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. December 8,1989, pp: 1293-97. New treatment for KS in the mouth Gay men with Kaposi Sarcoma sores in their mouths benefited from a drug called vinblastine injected directly into the sores, say Canadian doctors. If left untreated, KS sores may cause pain, bleeding, and difficulty swallowing. This new treatment causes fewer side effects than the usual treatment. Reference: J. Epstein and C. Scully. Intralesional Vinblastine fo r oral Kaposi Sarcoma in HIV infections. Lancet November 4,1989, pp: 1100-1. AZT. They also fear that the improvements seen with AZT may be temporary and deprive the HIV-infected person of greater future benefits from AZT. Reference: J. Cherfas. AZT still on trial. Science. November 17,1989, p: 882. J E F F R E Y Z U R L I N D E N AZT study continues in Europe Last summer the NIH ended an AZT study ahead of schedule because preliminary results showed that HIV-infected people without ARC or AIDS benefited from taking AZT. European scientists conducting a similar study are not so sure. Although AZT will be available to volunteers in the European study who want it, the study will continue. These European researchers believe that more time is needed to demonstrate a true benefit when otherwise healthy HIV-infected people take • Reference: B. Larder and S. Kemp. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to AZT. Science. December 1,1989, pp: 1155-57. Gonorrhea increasing in gay men BY protect the virus from AZT. They hope to develop new and simpler blood tests that wui determine if HIV-infected people taking AZT become resistant. Using current methods, it is almost impossible to know if strains of HIV are resistant to AZT. Researchers shed light on HIV enzyme Public health officials from Seattle, Washington report that the number of gay men with gonorrhea has tripled in the last year. Although the number o f men with gonorrhea remains small compared to ten years ago, it could mean that fewer gay men are playing safe and using condoms. Rectal gonorrhea and HIV are spread in the same way; and in the past, increases in the number of men with rectal gonorrhea heralded increases in the number of men infected with HIV. Reference: CDC. Trends in gonorrhea in homosexually active men in King County, Washington, 1989. MMWR. November 10, 1989, pp: 762-4. AZT-resistant HIV Researchers have long known that the drug AZT does not stop some strains of HIV. Now scientists at the Wellcome Research Labs have discovered the changes in HIV that To reproduce, HIV needs an enzyme called protease. Protease from HIV has now been pictured in great detail by scientists in London. A detailed understanding of the structure of protease will lead to drugs that inhibit protease and stop HIV from reproducing. Meanwhile, researchers in the United States are studying the interaction of protease and potential inhibitors. These researchers hope to design drugs that treat HIV-infections. Reference: L. Risto and others. X-ray analysis o f HIV-1 protienase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature. November 16,1989, pp: 299-302. M. Miller and others. Structure o f complex o f synthetic HIV-1 protease with substrate-based inhibitor at 2.3 A resolution. Science. December 1,1989, pp: 1149-51. Help keep JU S T OUT coming out. Send your non-tax deductible contribution to: 3000 For 10 Campaign JU S T OUT P.0. Box 15117 Portland, OR 97215 You U know it w hen you see it Like love at first sight, you'll know your new nome when you see it. My job as a professional Realtor is to make the process of finding your nome as easy as possible. You'll have my support from start to nnisn, through the search, financing, and escrow. I'll listen to your dreams and your needs and put my knowledge, experience and resources to work. Then comes the fun part. Like sinking into a comfortable chair, you'll know the one for you by how good it feels. Call me. I'll help you find your way home. Cathy Siemens Bridgetown UcH Ity (5 0 3 ) 2 8 7 -9 3 7 0 (503)238-0135 (home) \ With the AUTHENTIC AL-721® IMMUNE If it’s not ALTRIGEN It’s not AL721® M . Approved for Clincal Studies as an Antiviral Treatm ent by Government Agencies in England, France, Germany and Israel. ALTRIGEN EGG L E C I T H I N E T H I G E N C O R P O R A T I O N (800) 752-5721 • (800) 75-AL721 INQUIRIES INVITED: IRI DISTRIBUTION, INC. 4720 VINELAND AVE., SUITE AJCA LAKtrCAtT^ORNIA 91602 24-48 Hr Delivery e Throughout The USA ju st out ▼ 5 ▼ January 1990